Research programme: gabapentin controlled release - SCOLR

Drug Profile

Research programme: gabapentin controlled release - SCOLR

Alternative Names: CDT gabapentin - SCOLR

Latest Information Update: 07 Aug 2013

Price : $50

At a glance

  • Originator SCOLR Pharma
  • Class Amines; Aminobutyric acids; Analgesics; Antiepileptic drugs; Antimanics; Antiparkinsonians; Anxiolytics; Cyclohexanecarboxylic acids; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Neuropathic pain

Most Recent Events

  • 30 Jun 2013 SCOLR Pharma ceases it business operations
  • 30 Jun 2013 Discontinued - Preclinical for Neuropathic pain in USA (PO)
  • 09 May 2011 Research programme: gabapentin controlled release - SCOLR is available for licensing as of 31 Dec 2010. http://www.scolr.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top